<code id='4F56025C12'></code><style id='4F56025C12'></style>
    • <acronym id='4F56025C12'></acronym>
      <center id='4F56025C12'><center id='4F56025C12'><tfoot id='4F56025C12'></tfoot></center><abbr id='4F56025C12'><dir id='4F56025C12'><tfoot id='4F56025C12'></tfoot><noframes id='4F56025C12'>

    • <optgroup id='4F56025C12'><strike id='4F56025C12'><sup id='4F56025C12'></sup></strike><code id='4F56025C12'></code></optgroup>
        1. <b id='4F56025C12'><label id='4F56025C12'><select id='4F56025C12'><dt id='4F56025C12'><span id='4F56025C12'></span></dt></select></label></b><u id='4F56025C12'></u>
          <i id='4F56025C12'><strike id='4F56025C12'><tt id='4F56025C12'><pre id='4F56025C12'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:13
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          DeSantis can now import cheaper drugs. But will Biden get credit?
          DeSantis can now import cheaper drugs. But will Biden get credit?

          FloridagovernorandGOPpresidentialcandidateRonDeSantismadedrugimportationapolicypriority.CharlieNeibe

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas